top of page

SITC 2024: Immatics CEO Harpreet Singh shares an update on clinical data presented at SITC for the company's Gen 1 and Gen 2 PRAME cell therapies

blonca9
Nov 9, 2024
1 min read

He describes the Gen 1 data in melanoma and more, and compares it to what we have seen with competitor TIL data. Also, why the Gen 2 product is designed to reach more cancers that have less PRAME expression. Plus, previewing bispecific data that will come out in the coming months and 2025 and 2026 catalysts.

Recent Posts

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page